Cargando…
Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure
BACKGROUND: No data from controlled trials exists regarding the inflammatory response in patients with de novo heart failure (HF) complicating ST-elevation myocardial infarction (STEMI) and a possible role in the recovery of contractile function. We therefore explored the time course and possible as...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229310/ https://www.ncbi.nlm.nih.gov/pubmed/25390695 http://dx.doi.org/10.1371/journal.pone.0112359 |
_version_ | 1782344122439303168 |
---|---|
author | Husebye, Trygve Eritsland, Jan Arnesen, Harald Bjørnerheim, Reidar Mangschau, Arild Seljeflot, Ingebjørg Andersen, Geir Øystein |
author_facet | Husebye, Trygve Eritsland, Jan Arnesen, Harald Bjørnerheim, Reidar Mangschau, Arild Seljeflot, Ingebjørg Andersen, Geir Øystein |
author_sort | Husebye, Trygve |
collection | PubMed |
description | BACKGROUND: No data from controlled trials exists regarding the inflammatory response in patients with de novo heart failure (HF) complicating ST-elevation myocardial infarction (STEMI) and a possible role in the recovery of contractile function. We therefore explored the time course and possible associations between levels of inflammatory markers and recovery of impaired left ventricular function as well as levosimendan treatment in STEMI patients in a substudy of the LEvosimendan in Acute heart Failure following myocardial infarction (LEAF) trial. METHODS: A total of 61 patients developing HF within 48 hours after a primary PCI-treated STEMI were randomised double-blind to a 25 hours infusion of levosimendan or placebo. Levels of IL-6, CRP, sIL-6R, sgp130, MCP-1, IL-8, MMP-9, sICAM-1, sVCAM-1 and TNF-α were measured at inclusion (median 22 h, interquartile range (IQR) 14, 29 after PCI), on day 1, day 2, day 5 and 6 weeks. Improvement in left ventricular function was evaluated as change in wall motion score index (WMSI) by echocardiography. RESULTS: Only circulating levels of IL-8 at inclusion were associated with change in WMSI from baseline to 6 weeks, r = ÷0.41 (p = 0.002). No association, however, was found between IL-8 and WMSI at inclusion or peak troponin T. Furthermore, there was a significant difference in change in WMSI from inclusion to 6 weeks between patients with IL-8 levels below, compared to above median value, ÷0.44 (IQR÷0.57, ÷0.19) vs. ÷0.07 (IQR÷0.27, 0.07), respectively (p<0.0001). Levosimendan did not affect the levels of inflammary markers compared to control. CONCLUSION: High levels of IL-8 in STEMI patients complicated with HF were associated with less improvement in left ventricular function during the first 6 weeks after PCI, suggesting a possible role of IL-8 in the reperfusion-related injury of post-ischemic myocardium. Further studies are needed to confirm this hypothesis. TRIAL REGISTRATION: ClinicalTrials.gov NCT00324766 |
format | Online Article Text |
id | pubmed-4229310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42293102014-11-18 Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure Husebye, Trygve Eritsland, Jan Arnesen, Harald Bjørnerheim, Reidar Mangschau, Arild Seljeflot, Ingebjørg Andersen, Geir Øystein PLoS One Research Article BACKGROUND: No data from controlled trials exists regarding the inflammatory response in patients with de novo heart failure (HF) complicating ST-elevation myocardial infarction (STEMI) and a possible role in the recovery of contractile function. We therefore explored the time course and possible associations between levels of inflammatory markers and recovery of impaired left ventricular function as well as levosimendan treatment in STEMI patients in a substudy of the LEvosimendan in Acute heart Failure following myocardial infarction (LEAF) trial. METHODS: A total of 61 patients developing HF within 48 hours after a primary PCI-treated STEMI were randomised double-blind to a 25 hours infusion of levosimendan or placebo. Levels of IL-6, CRP, sIL-6R, sgp130, MCP-1, IL-8, MMP-9, sICAM-1, sVCAM-1 and TNF-α were measured at inclusion (median 22 h, interquartile range (IQR) 14, 29 after PCI), on day 1, day 2, day 5 and 6 weeks. Improvement in left ventricular function was evaluated as change in wall motion score index (WMSI) by echocardiography. RESULTS: Only circulating levels of IL-8 at inclusion were associated with change in WMSI from baseline to 6 weeks, r = ÷0.41 (p = 0.002). No association, however, was found between IL-8 and WMSI at inclusion or peak troponin T. Furthermore, there was a significant difference in change in WMSI from inclusion to 6 weeks between patients with IL-8 levels below, compared to above median value, ÷0.44 (IQR÷0.57, ÷0.19) vs. ÷0.07 (IQR÷0.27, 0.07), respectively (p<0.0001). Levosimendan did not affect the levels of inflammary markers compared to control. CONCLUSION: High levels of IL-8 in STEMI patients complicated with HF were associated with less improvement in left ventricular function during the first 6 weeks after PCI, suggesting a possible role of IL-8 in the reperfusion-related injury of post-ischemic myocardium. Further studies are needed to confirm this hypothesis. TRIAL REGISTRATION: ClinicalTrials.gov NCT00324766 Public Library of Science 2014-11-12 /pmc/articles/PMC4229310/ /pubmed/25390695 http://dx.doi.org/10.1371/journal.pone.0112359 Text en © 2014 Husebye et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Husebye, Trygve Eritsland, Jan Arnesen, Harald Bjørnerheim, Reidar Mangschau, Arild Seljeflot, Ingebjørg Andersen, Geir Øystein Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title | Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title_full | Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title_fullStr | Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title_full_unstemmed | Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title_short | Association of Interleukin 8 and Myocardial Recovery in Patients with ST-Elevation Myocardial Infarction Complicated by Acute Heart Failure |
title_sort | association of interleukin 8 and myocardial recovery in patients with st-elevation myocardial infarction complicated by acute heart failure |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229310/ https://www.ncbi.nlm.nih.gov/pubmed/25390695 http://dx.doi.org/10.1371/journal.pone.0112359 |
work_keys_str_mv | AT husebyetrygve associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT eritslandjan associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT arnesenharald associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT bjørnerheimreidar associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT mangschauarild associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT seljeflotingebjørg associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure AT andersengeirøystein associationofinterleukin8andmyocardialrecoveryinpatientswithstelevationmyocardialinfarctioncomplicatedbyacuteheartfailure |